.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
Company is investing more than €100 million in the expansion of the Halle site
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
Subscribe To Our Newsletter & Stay Updated
